Med BioGene Inc.
TSX VENTURE : MBI

Med BioGene Inc.

November 19, 2015 16:34 ET

Med BioGene Inc.: Grant of Stock Options

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 19, 2015) - Med BioGene Inc. ("MBI" or the "Company") (TSX VENTURE:MBI) announces that it has granted stock options to directors and senior officers to purchase up to an aggregate of 3,750,000 common shares in the capital of the Company. The options are exercisable at an exercise price of $0.05 and will expire on November 19, 2025.

About Med BioGene Inc.

MBI is a life science company based in Vancouver, British Columbia that is currently focused on managing the license and rights to GeneFX Lung™, a prognostic genomic based test procedure. MBI's common shares are listed for trading on the Exchange. For more information, please visit www.medbiogene.com.

This news release contains forward-looking statements and forward-looking information (together, "forward-looking statements") within the meaning of applicable Canadian and United States legislation. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include those risks set out in the Company's public documents filed on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed times frames or at all. Except where required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release

Contact Information